For research use only. Not for therapeutic Use.
GSK 626616 (CAT: I007119) is a selective inhibitor of the YAK3 (also known as DYRK3) kinase. YAK3 is a protein kinase that plays a role in various cellular processes, including cell proliferation and differentiation. By inhibiting YAK3, GSK 626616 has the potential to modulate these cellular processes and may have therapeutic applications in certain conditions. Specifically, GSK 626616 has been investigated as a chemoprotective agent for the treatment of chemotherapy-induced anemia, which is a common side effect of cancer treatment. Further research is being conducted to explore its efficacy and safety in this context.
| Catalog Number | I007119 |
| CAS Number | 1025821-33-3 |
| Synonyms | GSK-626616; GSK 626616; GSK626616.;(5Z)-2-(2,6-Dichloroanilino)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolone |
| Molecular Formula | C18H10Cl2N4OS |
| Purity | 98% |
| Target | DYRK |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | 0 - 4 °C for short term or -20 °C for long term |
| Overview of Clinical Research | <span style=”color:#000000;”><span style=”font-size:12px;”><span style=”font-family:arial,helvetica,sans-serif;”>GSK-626616 is a DYRK kinase inhibitor. The phase-I clinical trials was initiated in Chemotherapy-induced anaemia/Chemoprotection in Australia (PO) in 2006.</span></span></span> |
| IUPAC Name | (5Z)-2-(2,6-dichloroanilino)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazol-4-one |
| InChI | InChI=1S/C18H10Cl2N4OS/c19-11-2-1-3-12(20)16(11)23-18-24-17(25)15(26-18)9-10-4-5-13-14(8-10)22-7-6-21-13/h1-9H,(H,23,24,25)/b15-9- |
| InChIKey | RJPNRXFBYZVRIB-DHDCSXOGSA-N |
| SMILES | C1=CC(=C(C(=C1)Cl)NC2=NC(=O)C(=CC3=CC4=NC=CN=C4C=C3)S2)Cl |
| Reference | <br /> |
